Platelet derived growth factor BB: a “must-have” therapeutic target “redivivus” in ovarian cancer
Background: We aimed to validate PDGF-BB protein expression by RNAscope, a sensitive method for PDGF-BB mRNA evaluation on paraffin embedded (FFPE) specimens of ovarian tumors. Materials and Methods: Seventy-five FFPE ovarian cancer biopsies were assessed by immunohistochemistry followed by PDGF-BB...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 22, 2016
|
| In: |
Cancer genomics & proteomics
Year: 2016, Volume: 13, Issue: 6, Pages: 511-517 |
| ISSN: | 1790-6245 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: http://cgp.iiarjournals.org/content/13/6/511
|
| Author Notes: | Anca Maria Cimpean, Ionut Marcel Cobec, Raluca Amalia Ceaușu, Roxana Popescu, Anca Tudor and Marius Raica |
| Summary: | Background: We aimed to validate PDGF-BB protein expression by RNAscope, a sensitive method for PDGF-BB mRNA evaluation on paraffin embedded (FFPE) specimens of ovarian tumors. Materials and Methods: Seventy-five FFPE ovarian cancer biopsies were assessed by immunohistochemistry followed by PDGF-BB mRNA RNAscope validation. Results and Conclusion: Dual PDGF-BB expression in tumor and stromal cells have been observed, being highly suggestive for PDGF-BB mediated stromal-tumor cells reciprocal interaction in ovarian cancer (p=0.008). It seems that the nuclear expression of the PDGF-BB represents a negative prognostic factor in ovarian tumors. Being a controversial issue in the literature, PDGF-BB nuclear expression detected by immunohistochemistry was validated by RNAscope in situ hybridization. More than 65% of cases had PDGF-BB mRNA amplification, confirming immunohistochemical results. We herein validated PDGF-BB as a potential therapeutic and prognostic tool of ovarian cancer aggressiveness. |
|---|---|
| Item Description: | Gesehen am 04.05.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1790-6245 |